大约 40% 的 MRI 程序使用钆基造影剂 (GBCA)。尽管最初认为风险很小，但长期使用它们强调需要降低毒性并开发更有效的具有延长血液保留的 GBCA。纳米材料的进步改进了 GBCA，增强了 MRI 诊断。本研究合成并表征了作为优质 MRI 造影剂的纳米结构钆 (III) 胶束。配合物 [Gd(L)2]（其中 L 是 N-烷基-N-甲基葡糖胺表面活性剂系列（L8、L10 或 L12、L10）的配体）在水溶液中形成纳米结构胶束。 Gd(L8)2 和 Gd(L10)2 弛豫率在不同浓度下保持稳定。与 Gd-DTPA 相比，Gd(III) 胶束显示出增强的 T1 加权 MRI 对比度。 Gd(L12)2胶束对B16F10黑色素瘤细胞(IC50 42.5±2.2μM)和L292L929成纤维细胞(IC50 52.0±2.5μM)表现出细胞毒性，选择性指数为1.2。小鼠大脑 T2 加权图像的体内应用表明，纳米结构 Gd(III) 胶束是有前景的 MRI 造影剂，可用于靶向健康器官或肿瘤。版权所有 © 2024。由 Elsevier Inc. 出版。

Gadolinium-based contrast agents (GBCAs) are used in around 40 % of MRI procedures. Despite initial perceptions of minimal risk, their long-term use has emphasized the need to reduce toxicity and develop more efficient GBCAs with extended blood retention. Advancements in nanomaterials have led to improved GBCAs, enhancing MRI diagnostics. This study synthesizes and characterizes nanostructured gadolinium(III) micelles as superior MRI contrast agents. The complexes, [Gd(L)2], where L is a ligand of the N-alkyl-N-methylglucamine surfactant series (L8, L10 or L12, L10), form nanostructured micelles in aqueous solution. Gd(L8)2 and Gd(L10)2 relaxivities remained stable across concentrations. Compared to Gd-DTPA, Gd(III) micelles showed enhanced T1-weighted MRI contrast. Gd(L12)2 micelles exhibited cytotoxicity against B16F10 melanoma cells (IC50 42.5 ± 2.2 μM) and L292L929 fibroblasts (IC50 52.0 ± 2.5 μM), with a selectivity index of 1.2. In vivo application in mice brain T2-weighted images suggests nanostructured Gd(III) micelles are promising MRI contrast agents for targeting healthy organs or tumors.Copyright © 2024. Published by Elsevier Inc.